Charles River Laboratories and AstraZeneca Renew Strategic Partnership Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Charles River Laboratorie (CRL) Misses Q2 EPS by 1c; Extends Agreement with AstraZeneca (AZN)
July 30, 2015 7:13 AM EDTCharles River Laboratorie (NYSE: CRL) reported Q2 EPS of $0.96, $0.01 worse than the analyst estimate of $0.97. Revenue for the quarter came in at $339.6 million versus the consensus estimate of $338.3 million.
Charles River Laboratorie sees FY2015 EPS of $3.60-$3.70, versus the consensus of $3.64.
The company also announced announced that it has extended its initial three-year partnership with AstraZeneca (NYSE:... More
